Mylan and Biocon ended 2017 with more positive news for their biosimilar program; on December 29, 2017, the partnership announced that Brazil’s National Sanitary Surveillance Agency (ANVISA) had approved their trastuzumab biosimilar.
Mylan and Biocon ended 2017 with more positive news for their biosimilar program; on December 29, 2017, the partnership announced that Brazil’s National Sanitary Surveillance Agency (ANVISA) had approved their trastuzumab biosimilar for the treatment of overexpressing HER2-positive metastatic breast cancer, HER2-positive early breast cancer and HER2-positive advanced gastric cancer. The drug, which will be sold under the brand name Zedora, is the first biosimilar trastuzumab to be approved in Brazil.
In a statement, Mylan’s CEO, Heather Bresch, highlighted the fact that the biosimilar could bring about greater patient access to biologic treatment for cancer: “The number of women diagnosed with breast cancer in Brazil is increasing. Sadly, many of the women with HER2-positive metastatic breast cancer in Brazil do not have access to [trastuzumab] through the country's public health system. The approval of Zedora…is an important step in our efforts to increase access to this critical product for patients with certain breast and gastric cancers and reduce the overall financial burden for health systems around the world."
The ANVISA approval was granted through Mylan and Biocon’s Brazilian partner, Libbs Farmaceutica. Libbs is a pharmaceutical company that currently markets approximately 90 drug brands in 200 presentations for indications in gynecology, neurology, cardiology, oncology, and dermatology. The company’s biotechnology unit, Biotech, launched in 2016, is responsible for the production of its monoclonal antibodies.
Earlier in December 2017, the Mylan and Biocon gained FDA clearance for the same drug, which will be marketed in the United States under the brand name Ogivri. The FDA approval was the first for a biosimilar trastuzumab, and the second for an anticancer therapy in the United States.
The partnership has also re-submitted an application for the drug to the European Medicines Agency (EMA) after its first application was withdrawn as the companies awaited re-inspection of a manufacturing facility in India. Should the Mylan and Biocon product gain EMA clearance, the drug will eventually compete with Celltrion’s recently EMA-approved biosimilar trastuzumab, Herzuma, as well as Samsung Bioepis’ EMA-approved product, Ontruzant.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.